Bs. Auerbach et al., DOSE-RESPONSE TO A 2-COMPONENT ACELLULAR PERTUSSIS-VACCINE IN INFANTSAND COMPARISON WITH WHOLE-CELL VACCINE, Biologicals (Print), 26(2), 1998, pp. 145-153
Citations number
46
Categorie Soggetti
Biothechnology & Applied Migrobiology","Pharmacology & Pharmacy","Biochemical Research Methods",Biology
in an effort to determine the optimal dose of pertussis toroid (PT) an
d filamentous haemagglutinin (FHA) for use in a cellular pertussis vac
cines we compared the immunogenicity and safety of acellular pertussis
vaccine combined with diphtheria and tetanus toxoids containing 12.5
mu g (DTaP-12.5) or 25 mu g (DTaP-25) each of PT and FHA with a whole-
cell pertussis vaccine in infants immunized at 2, 4 and 6 months of ag
e. Recipients of acellular vaccines developed higher anti-FHA concentr
ations and more rapid anti-PT serological responses than infants who r
eceived whole-cell pertussis vaccine combined with diphtheria and teta
nus toxoids (DTP). A dose response was noted; infants immunized with D
TaP-25 developed significantly (P < 0.03) higher anti-FHA and anti-PT
levels than infants who received DTaP-12.5. No rise in agglutinin titr
es was noted for recipients of the acellular vaccines although this va
ccine stimulated increases in agglutinins when given as the fourth or
fifth dose to children who had received three doses of DTP. The rates
of erythema, induration, pain, irritability, crying, increased sleepin
ess,and decreased appetite were significantly (P less than or equal to
0.05) lower in infants who received a cellular vaccines than in infan
ts who received DTP. When the data from injections at 2, 4 and 6 month
s of age were combined, no significant differences in the rates of any
adverse event were noted for recipients of DTaP-12.5 Sor DTaP-25. The
rates of most adverse reactions following DTP decreased from the firs
t to the third immunization except fever, which increased. For a cellu
lar vaccine recipients, the rates of fever and erythema increased some
what from the first to the third injection but remained far below the
rates following DTP. The acellular vaccine was safe and immunogenic, a
nd a dose-response effect was demonstrated. (C) 1998 The International
Association of Biological Standardization.